June - 2022

top of page

Sage Group News

Kinnov Therapeutics Completes Successful Phase 2 study for Alcohol Use Disorder

Sage’s new client, Kinnov Therapeutics, is a French-based company focused on one of the major unmet global healthcare challenges,...

Hatchtech appoints Sage Group to divest its FDA-approved Xeglyze® for head lice treatment

Hatchtech has engaged the Sage Group to manage the sale process for its lead asset Xeglyze®. Xeglyze is a patent protected, single...

bottom of page